With FDA Approval for RNAi Drug, Arrowhead Pharma Starts Price War With Rival Ionis

Arrowhead Pharmaceuticals’ RNAi drug plozasiran, brand name Redemplo, is now the second FDA-approved therapy for familial chylomicronemia syndrome, an inherited lipid disorder. Beyond its claims of safety and dosing advantages, Arrowhead set a dramatically lower price for its first commercial product, which will compete against an Ionis Pharmaceuticals drug. The post With FDA Approval for…

Read More

Struggling UnitedHealth Group is a Huge Smoking Black Box

By JEFF GOLDSMITH In mid-April 2025, UnitedHealth Group (UNH) reported its 1Q25 operating results, including a modest shortfall in expected earnings and lowered its 2025 earnings forecast by 12%. The company blamed accelerating medical costs and federal policy changes for their most profitable service line, Medicare Advantage. Market reaction was swift and savage. UNH stock…

Read More

Addressing Operational Inefficiencies in Healthcare Finance to Drive Better Business Decisions

Fragmented finance systems have long caused operational challenges. By addressing this, CFOs can optimize and streamline many finance processes to improve compliance readiness and create time for business-driven decisions that support business objectives. The post Addressing Operational Inefficiencies in Healthcare Finance to Drive Better Business Decisions appeared first on MedCity News.

Read More